Tools
Biotinidase Deficiency
Introduction
Vitamins are vital components of daily biochemical reactions and molecular processes. These substances function as cofactors, antioxidants, hormones, and mediators of vision. Vitamin deficiencies can result from inadequate dietary intake or abnormal intracellular processing. Biotin is an essential vitamin obtained from the diet and efficiently recycled for continued use. Failure of this recycling mechanism due to enzyme deficiency causes significant morbidity and mortality. Biotinidase deficiency, an autosomal recessive condition, is the most common cause.
Biotin serves as a coenzyme for 4 carboxylation enzymes: 3-methylcrotonyl-CoA carboxylase (MCC), pyruvate carboxylase, acetyl-CoA carboxylase (ACC), and propionyl-CoA carboxylase (PCC). Biotinidase deficiency is classified as profound (0%-10% enzyme activity) or partial (10%-30% enzyme activity), with classification guiding the treatment approach. Clinical manifestations vary and may involve ophthalmologic, neurologic, dermatologic, and immunologic systems.[1][2] Partial cases are often asymptomatic or have mild symptoms, whereas profound cases may progress to seizures, developmental delay, vision or hearing loss, metabolic acidosis, and, without treatment, coma or death. Early recognition is critical, as prompt biotin supplementation can prevent or minimize irreversible complications.[3]
Management is straightforward because patients require consistent, high doses of biotin. This intervention can reverse or halt the progression of many symptoms when initiated promptly. Early diagnosis and treatment can prevent developmental delay, reduce long-term disability, and improve quality of life.[4][5][6]
Biotinidase deficiency is included in many newborn screening programs worldwide and in all 50 states in the U.S.[7][8][9] The therapeutic role of biotin in carboxylase deficiencies was first investigated approximately 40 years ago. In 1971, patients with β-methylcrotonylglycinuria, a carboxylase deficiency, demonstrated clinical response to biotin supplementation.[10] A decade later, Wolf et al identified a neonatal form of multiple carboxylase deficiency caused by biotin deficiency.[11][12]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Biotinidase deficiency follows an autosomal recessive inheritance pattern caused by 2 pathogenic variants in the BTD gene, located on chromosome 3p25.1. The BTD gene encodes the biotinidase enzyme, which recycles biotin and enables the cofactor to be available for carboxylase activity.[13] Biotinidase converts biocytin into free biotin by cleaving a lysine residue, thereby replenishing the biotin pool for subsequent reactions. In the absence of adequate biotin, carboxylase enzymes (MCC, ACC, PCC, and pyruvate carboxylase) cannot catalyze their reactions correctly, resulting in substrate accumulation that produces significant metabolic toxicity and clinical manifestations.
Epidemiology
Biotinidase deficiency is a rare disorder with an incidence ranging from 1 per 40,000 to 1 per 60,000 births worldwide. In 2006, the incidence of profound cases was 1 per 80,000 births, and the incidence of partial cases ranged from 1 per 31,000 to 1 per 40,000 births in the U.S. The estimated carrier frequency is 1 in 123 individuals. Incidence rates vary by country.[14][15]
Populations with higher rates of consanguinity demonstrate an increased incidence of biotinidase deficiency. This finding has been reported in Turkey and the Kingdom of Saudi Arabia. A higher incidence has also been observed in Hispanic infants born in the western U.S. and in Italian infants.[16][17][16] In contrast, a lower incidence has been reported in African-American populations.
Newborn screening for biotinidase deficiency is now routinely performed in all U.S. states and in more than 25 countries worldwide.[18][19] Profound biotinidase deficiency typically manifests within the first 6 months of life, although the age of onset can vary.[20][21] Symptoms can appear as early as the 1st week of life and as late as age 10 years, with a mean age of onset of 3.5 months.
Pathophysiology
Biotin is a water-soluble B-complex vitamin. This micronutrient is present in several dietary sources, including milk, raw egg yolk, organ meats such as liver and kidney, Swiss chard, leafy green vegetables, and brewer’s yeast. Endogenous biotin is also synthesized by colonic flora within the large intestine.
Apocarboxylase becomes holocarboxylase through biotin conjugation, a process mediated by holocarboxylase synthetase. Holocarboxylase undergoes proteolytic degradation, releasing biotinyl-peptides and biocytin. Biotinidase recycles biotin from these compounds, thereby replenishing the free biotin pool and maintaining its availability for carboxylases.
Biotinidase deficiency results in insufficient free biotin for 4 critical carboxylases, leading to metabolic blocks in their respective pathways. Pyruvate carboxylase deficiency causes the accumulation of lactic acid and alanine. Reduced PCC activity leads to elevated propionate, 3-hydroxypropionate, and methylcitrate. Impaired MCC-mediated catalysis results in the buildup of 3-methylcrotonylglycine and 3-hydroxyisovalerate. ACC insufficiency causes acetyl-CoA accumulation. These combined biochemical abnormalities produce variable neurologic and dermatologic manifestations of biotinidase deficiency.
Histopathology
The extent of pathologic central nervous system findings in patients with biotinidase deficiency correlates with the severity of the clinical condition before death. The observed features resemble those of Wernicke encephalopathy or Leigh syndrome, although the pathologic brain lesions are more widespread. Myelin involvement appears pronounced compared with neuronal or axonal involvement. Necrotic lesions have been reported in the pons, hypothalamus, medulla, and hippocampus. Microscopic examination demonstrates microcavitation, gliosis, and capillary proliferation in affected regions. Extensive cerebral edema may also be present in many major white matter tracts.
History and Physical
Biotinidase deficiency is classified as either profound or partial. Individuals with less than 10% of normal enzymatic activity are diagnosed with profound biotinidase deficiency, whereas those with 10% to 30% activity are classified as having partial disease. This distinction is clinically important because prognosis and treatment differ between the 2 categories.
Profound biotinidase deficiency typically presents in early infancy with variable neurologic and cutaneous manifestations. Neurologic findings may include seizures, hypotonia, ataxia, developmental delay, spastic paresis, and progressive visual impairment leading to optic atrophy in profound cases or optic neuropathy in partial cases.[22][23][24][23] Sensorineural hearing loss, lethargy, coma, and death may also occur if the condition is left untreated.[25] Cutaneous manifestations frequently include a skin rash, alopecia, conjunctivitis, and seborrheic dermatitis. Additional findings may include recurrent viral and fungal infections due to immune dysfunction, as well as respiratory manifestations such as apnea, tachypnea, or stridor. Metabolic derangements are common and may include ketolactic acidosis, organic aciduria, or hyperammonemia.
Early detection and prompt biotin therapy render most symptoms reversible. Vision changes, hearing loss, and developmental delay are irreversible in profound cases if present.[26] Optic neuropathy in partial biotinidase deficiency may resolve with treatment. Untreated patients risk metabolic decompensation, coma, and death.
Partial biotinidase deficiency can present anytime from infancy to adulthood. The manifestations may range from mild cutaneous findings, such as rash and alopecia, to severe neurologic manifestations, including seizures, hypotonia, and developmental delay. Symptoms typically occur during periods of physiologic stress, such as acute illness. Some individuals remain entirely asymptomatic throughout life.
Evaluation
Diagnosis of biotinidase deficiency is established through newborn screening or targeted testing of symptomatic patients. Enzyme activity is measurable in serum or plasma. When enzyme levels are abnormal, genetic testing may be performed to evaluate for BTD mutations.[27] Diagnosis is confirmed by demonstrating deficient biotinidase enzyme activity in serum or plasma or by identifying biallelic pathogenic or likely pathogenic BTD variants when enzymatic results are ambiguous. A consensus has not been established regarding standardized clinical diagnostic criteria for biotinidase deficiency.
Laboratory findings may include elevated lactic acid and ammonia levels in blood or urine. Additional recommended investigations include arterial blood gas analysis, serum amino acid quantification, and serum chemistry panels. Urinary studies may include assessment for ketones and measurement of urinary organic acids.
Brain magnetic resonance imaging in untreated patients during acute crisis frequently demonstrates diffuse cerebral and cerebellar T2-hyperintensity, cerebral swelling, bilateral compensatory ventriculomegaly, and delayed myelination.[28][29][30] Magnetic resonance spectroscopy provides functional information about brain metabolism. Although not widely available, this modality may help characterize brain pathology in vivo. Positron emission tomography can reveal changes in cerebral metabolic activity before and after biotin administration. Computed tomography may show bilateral basal ganglia calcifications that may not be detected on magnetic resonance imaging.
Biotinidase deficiency should be considered in patients with recurrent fungal, viral, or skin infections.[31] Electroencephalography may demonstrate diffuse polyspike discharges or rhythmic diffuse spike-and-wave discharges. These findings typically normalize completely after biotin treatment. Ophthalmologic evaluation with dilated funduscopy is useful for detecting scotomata and optic nerve atrophy. Visual evoked potentials and visual field testing further delineate the extent of optic nerve involvement.
Treatment / Management
Treatment for biotinidase deficiency is lifelong but relatively straightforward. No formal clinical practice guidelines have been published. The recommended initial therapy is oral biotin replacement at a starting dose of 5 to 20 mg daily. Seizures and movement disorders typically improve within hours to days of treatment initiation. Cutaneous manifestations may require several weeks to resolve.
If symptoms persist despite initial dosing, an increase to 40 mg daily is recommended. Children with developmental delays may regain previously lost milestones or acquire new ones. Recovery depends on the timing of treatment initiation and the degree of neurologic damage sustained prior to diagnosis. Treatment prevents further progression of irreversible neurologic damage.[32]
Both symptomatic and asymptomatic patients should undergo audiologic evaluation, growth parameter assessment, and genetic counseling. Asymptomatic infants should also be evaluated by neurology to screen for hypotonia or seizures.
Symptomatic patients require a more comprehensive assessment. Recommended evaluations include nutrition consultation, neurological examination, ophthalmologic evaluation, developmental assessment, detailed skin examination, immunologic history, and respiratory screening. Additional interventions may be indicated based on comorbidities or complications identified during these evaluations.
Differential Diagnosis
Biotinidase deficiency presents with a constellation of neurologic, dermatologic, and immunologic findings that closely resemble other inherited and acquired disorders. The differential diagnosis should thus include the following:
- Isolated carboxylase deficiency
- Dietary biotin deficiency
- Holocarboxylase synthetase deficiency
- Meningitis (seizures and rash)
- Primary immunodeficiency (fungal and bacterial infections)
- Sensorineural deafness
- Acrodermatitis enteropathica
- Autism (developmental delay and inattentiveness)
- Myelopathies
- Neuromyelitis optica
- Optic atrophy [33]
- Seborrheic dermatitis [34]
- Infantile spasms
- Vitamin B1 deficiency
- Neurocutaneous disorders
- Refsum disease
- Arsenic poisoning
- Inborn errors of metabolism
Careful differentiation from these conditions is essential to ensure timely diagnosis and treatment. A systematic approach that integrates clinical evaluation, newborn screening results, confirmatory enzyme assays, and genetic testing is essential to diagnose biotinidase deficiency and distinguish it accurately from its mimics.
Prognosis
Biotinidase deficiency carries a favorable prognosis when identified early and managed with continuous care.[35] Inclusion of biotinidase deficiency in newborn screening programs has been instrumental in improving patient outcomes. Asymptomatic patients have an excellent prognosis when treatment is initiated before symptom onset. Symptomatic patients experience improvement in most clinical manifestations with pharmacologic biotin therapy. However, neurologic deficits present at the time of diagnosis are typically irreversible.[36]
Complications
Undetected and untreated biotinidase deficiency in infancy can result in severe and potentially irreversible complications, including optic neuropathy, acquired retinal dysplasia, and sensorineural deafness.[37] Neurologic sequelae, such as developmental disability and paresis, may arise. Metabolic derangements may include hyperammonemia or organic aciduria. Recurrent infections are common and may lead to significant morbidity. The condition can progress to coma and death in severe cases. Awareness of these complications underscores the importance of newborn screening and timely initiation of biotin therapy.
Consultations
An interprofessional team approach is essential to achieve early diagnosis and initiate prompt treatment for biotinidase deficiency. Specialty consultations should include the following:
- Metabolic team/medical genetics
- Neonatology
- Nutrition
- Pediatrics
- Radiology
- Neurology
- Ophthamology
- Physiotherapy
In pediatric patients, collaboration among a pediatric neurologist, geneticist, and metabolic disorder specialist is recommended for comprehensive evaluation and management.[38]
Deterrence and Patient Education
Families must understand that biotinidase deficiency requires lifelong and consistent treatment because the disorder involves a primary defect in the body’s ability to recycle biotin. Complications may be prevented through early diagnosis and management, but some manifestations remain irreversible. This disorder is inherited in an autosomal recessive manner. Consequently, families should receive counseling that the risk of having another affected child is 25% with each pregnancy involving the same 2 partners.
Enhancing Healthcare Team Outcomes
Early diagnosis and treatment of biotinidase deficiency are critical to reducing morbidity and mortality. Management requires a coordinated interprofessional team approach. Prompt evaluation by neonatologists, pediatricians, and geneticists is essential to prevent irreversible damage and complications in affected children. Biochemical metabolite studies confirm the diagnosis, and newborn screening programs in the U.S. and many other countries routinely include testing for biotinidase deficiency. Treatment must be initiated immediately upon detection and should not be delayed. Given the urgency of intervention, healthcare providers must be familiar with the clinical presentation and management strategies for biotinidase deficiency to ensure optimal patient outcomes.
A coordinated interprofessional effort is essential for the diagnosis and management of biotinidase deficiency. The team should include physicians such as geneticists, pediatricians, neonatologists, and neurologists, along with advanced practitioners, therapists, nursing staff, and pharmacists. Detection typically occurs through newborn screening. The first providers to address an abnormal screen are usually pediatricians, neonatologists, or advanced practitioners.
The healthcare team must recognize the symptoms, appreciate the urgency of treatment initiation, and promptly consult a medical geneticist. Under the guidance of the geneticist, treatment should be implemented without delay. Effective communication among all providers is critical to reducing morbidity and mortality.
Radiologists may identify early brain changes that aid in diagnosis, particularly when the condition has been missed initially, and may help distinguish biotinidase deficiency from other brain and spinal cord disorders. Pediatricians and primary care physicians may detect partial biotinidase deficiency and must be able to recognize its clinical features. When neurological damage is present, physiotherapists play a role in treating hypotonia and developmental disability. Given the severe complications that may occur and the markedly improved outcomes with timely treatment, a coordinated interprofessional approach is necessary to optimize clinical outcomes and improve quality of life in affected children.
References
Chedrawi AK, Ali A, Al Hassnan ZN, Faiyaz-Ul-Haque M, Wolf B. Profound biotinidase deficiency in a child with predominantly spinal cord disease. Journal of child neurology. 2008 Sep:23(9):1043-8. doi: 10.1177/0883073808318062. Epub 2008 Jul 21 [PubMed PMID: 18645204]
Level 3 (low-level) evidenceYang Y, Yang JY, Chen XJ. Biotinidase deficiency characterized by skin and hair findings. Clinics in dermatology. 2020 Jul-Aug:38(4):477-483. doi: 10.1016/j.clindermatol.2020.03.004. Epub 2020 Apr 1 [PubMed PMID: 32972606]
Dahiphale R, Jain S, Agrawal M. Biotinidase deficiency. Indian pediatrics. 2008 Sep:45(9):777-9 [PubMed PMID: 18820388]
Level 3 (low-level) evidenceAdam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Wolf B. Biotinidase Deficiency. GeneReviews(®). 1993:(): [PubMed PMID: 20301497]
Ghazal S, Ali A, Bin Arif T, Memon F, Malik L. Biotinidase Deficiency With Suspected Sotos Syndrome: A Rare Entity. Cureus. 2020 May 7:12(5):e8000. doi: 10.7759/cureus.8000. Epub 2020 May 7 [PubMed PMID: 32523854]
Sondhi V, Sharma S. Vitamin-Responsive Movement Disorders in Children. Annals of Indian Academy of Neurology. 2020 May-Jun:23(3):325-331. doi: 10.4103/aian.AIAN_678_19. Epub 2020 Jun 5 [PubMed PMID: 32606520]
Bozduman Çelebi S, Akdağ B, Cimbar H, Dağ C, Topal F, Noyan B, Önal H. Developmental outcomes of children with biotinidase deficiency and the psychological state of their parents. European journal of pediatrics. 2025 Mar 10:184(3):236. doi: 10.1007/s00431-025-06066-z. Epub 2025 Mar 10 [PubMed PMID: 40064641]
Jamaleddin T, El-Akouri K, Abiib S, Mitri R, Ramaswamy M, Musa S, Ali R, Shahbeck N, Al Rifai H, Abdoh G, Ben-Omran T, Al-Dirbashi OY, Al-Shafai M. Qatar's National Expanded Metabolic Newborn Screening Program: Incidence and Outcomes. International journal of neonatal screening. 2025 Jun 30:11(3):. doi: 10.3390/ijns11030050. Epub 2025 Jun 30 [PubMed PMID: 40700042]
Torres-Sepúlveda MDR, Martínez de Villarreal LE, Villarreal-Pérez JZ, Ruiz Herrera MDC, Arredondo Vázquez PDC, Treviño-Morales AK. Outcome of Expanded Newborn Screening Among 194 000 Neonates at Northeast México. Global pediatric health. 2024:11():2333794X241280830. doi: 10.1177/2333794X241280830. Epub 2024 Sep 20 [PubMed PMID: 39315058]
Gompertz D, Draffan GH, Watts JL, Hull D. Biotin-responsive beta-methylcrotonylglycinuria. Lancet (London, England). 1971 Jul 3:2(7714):22-4 [PubMed PMID: 4103667]
Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Annals of neurology. 1985 Nov:18(5):614-7 [PubMed PMID: 4073853]
Tsao CY, Kien CL. Complete biotinidase deficiency presenting as reversible progressive ataxia and sensorineural deafness. Journal of child neurology. 2002 Feb:17(2):146 [PubMed PMID: 11952077]
Level 3 (low-level) evidenceKasapkara ÇS, Akar M, Özbek MN, Tüzün H, Aldudak B, Baran RT, Tanyalçın T. Mutations in BTD gene causing biotinidase deficiency: a regional report. Journal of pediatric endocrinology & metabolism : JPEM. 2015 Mar:28(3-4):421-4. doi: 10.1515/jpem-2014-0056. Epub [PubMed PMID: 25423671]
Canda E, Kalkan Uçar S, Çoker M. Biotinidase Deficiency: Prevalence, Impact And Management Strategies. Pediatric health, medicine and therapeutics. 2020:11():127-133. doi: 10.2147/PHMT.S198656. Epub 2020 May 4 [PubMed PMID: 32440248]
Pindolia K, Chen J, Cardwell C, Cui X, Chopp M, Wolf B. Neurological deficits in mice with profound biotinidase deficiency are associated with demylination and axonal degeneration. Neurobiology of disease. 2012 Sep:47(3):428-35. doi: 10.1016/j.nbd.2012.04.016. Epub 2012 May 8 [PubMed PMID: 22579707]
Level 3 (low-level) evidenceCowan TM, Kazerouni NN, Dharajiya N, Lorey F, Roberson M, Hodgkinson C, Schrijver I. Increased incidence of profound biotinidase deficiency among Hispanic newborns in California. Molecular genetics and metabolism. 2012 Aug:106(4):485-7. doi: 10.1016/j.ymgme.2012.05.017. Epub 2012 May 30 [PubMed PMID: 22698809]
Funghini S, Tonin R, Malvagia S, Caciotti A, Donati MA, Morrone A, la Marca G. High frequency of biotinidase deficiency in Italian population identified by newborn screening. Molecular genetics and metabolism reports. 2020 Dec:25():100689. doi: 10.1016/j.ymgmr.2020.100689. Epub 2020 Dec 5 [PubMed PMID: 33312878]
Hsu RH, Chien YH, Hwu WL, Chang IF, Ho HC, Chou SP, Huang TM, Lee NC. Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population. Orphanet journal of rare diseases. 2019 Jan 7:14(1):6. doi: 10.1186/s13023-018-0992-2. Epub 2019 Jan 7 [PubMed PMID: 30616616]
Hong X, Kumar AB, Ronald Scott C, Gelb MH. Multiplex tandem mass spectrometry assay for newborn screening of X-linked adrenoleukodystrophy, biotinidase deficiency, and galactosemia with flexibility to assay other enzyme assays and biomarkers. Molecular genetics and metabolism. 2018 Jun:124(2):101-108. doi: 10.1016/j.ymgme.2018.03.012. Epub 2018 Mar 29 [PubMed PMID: 29680633]
Venkataraman V, Balaji P, Panigrahi D, Jamal R. Biotinidase deficiency in childhood. Neurology India. 2013 Jul-Aug:61(4):411-3. doi: 10.4103/0028-3886.117614. Epub [PubMed PMID: 24005734]
Level 3 (low-level) evidenceThodi G, Schulpis KH, Molou E, Georgiou V, Loukas YL, Dotsikas Y, Papadopoulos K, Biti S. High incidence of partial biotinidase deficiency cases in newborns of Greek origin. Gene. 2013 Jul 25:524(2):361-2. doi: 10.1016/j.gene.2013.04.059. Epub 2013 Apr 30 [PubMed PMID: 23644139]
Level 3 (low-level) evidencePatra S, Senthilnathan G, Bhari N. Acrodermatitis enteropathica-like skin eruption with neonatal seizures in a child with biotinidase deficiency. Clinical and experimental dermatology. 2020 Mar:45(2):266-267. doi: 10.1111/ced.14053. Epub 2019 Aug 21 [PubMed PMID: 31323123]
Wolf B. Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss. Molecular genetics and metabolism. 2015 Nov:116(3):113-8. doi: 10.1016/j.ymgme.2015.08.012. Epub 2015 Sep 3 [PubMed PMID: 26358973]
Cao AA, Brown MM, Lee MS, Rashidi AM, Rashidi V. Biotinidase Deficiency Induced Optic Neuropathy: A Case Report and Literature Review. Neuro-ophthalmology (Aeolus Press). 2025:49(3):224-231. doi: 10.1080/01658107.2024.2424209. Epub 2025 Feb 18 [PubMed PMID: 40190376]
Level 3 (low-level) evidenceKannan B, Navamani HK, Jayaseelan VP, Arumugam P. A Rare Biotinidase Deficiency in the Pediatrics Population: Genotype-Phenotype Analysis. Journal of pediatric genetics. 2023 Mar:12(1):1-15. doi: 10.1055/s-0042-1757887. Epub 2022 Nov 1 [PubMed PMID: 36684547]
Senanayake DN, Jasinge EA, Pindolia K, Wanigasinghe J, Monaghan K, Suchy SF, Wei S, Jaysena S, Wolf B. First contiguous gene deletion causing biotinidase deficiency: The enzyme deficiency in three Sri Lankan children. Molecular genetics and metabolism reports. 2015 Mar:2():81-84. doi: 10.1016/j.ymgmr.2015.01.005. Epub 2015 Feb 7 [PubMed PMID: 28649532]
Asgari A, Rouhi Dehnabeh S, Zargari M, Khani S, Mozafari H, Varasteh A, Keyfi F, Barzegari M, Hasanzaeh R, Khatami S. Clinical, Biochemical and Genetic Analysis of Biotinidase Deficiency in Iranian Population. Archives of Iranian medicine. 2016 Nov:19(11):774-778 [PubMed PMID: 27845546]
Singh P, Gurnani R, Rawat A, Parihar A. Brain MRI findings in an infant with congenital biotinidase deficiency. BMJ case reports. 2021 Oct 8:14(10):. doi: 10.1136/bcr-2021-246167. Epub 2021 Oct 8 [PubMed PMID: 34625444]
Level 3 (low-level) evidenceRanjan RS, Taneja S, Singh A, Gupta V. Congenital biotinidase deficiency - MRI findings in two cases. The Indian journal of radiology & imaging. 2019 Jan-Mar:29(1):99-103. doi: 10.4103/ijri.IJRI_159_18. Epub [PubMed PMID: 31000952]
Level 3 (low-level) evidenceBiswas A, McNamara C, Gowda VK, Gala F, Sudhakar S, Sidpra J, Vari MS, Striano P, Blaser S, Severino M, Batzios S, Mankad K. Neuroimaging Features of Biotinidase Deficiency. AJNR. American journal of neuroradiology. 2023 Mar:44(3):328-333. doi: 10.3174/ajnr.A7781. Epub 2023 Feb 9 [PubMed PMID: 36759144]
Kiykim E, Kiykim A, Cansever MS, Zeybek CA. Biotinidase deficiency mimicking primary immune deficiencies. BMJ case reports. 2015 May 8:2015():. doi: 10.1136/bcr-2014-209275. Epub 2015 May 8 [PubMed PMID: 25956498]
Level 3 (low-level) evidenceFerreira P, Chan A, Wolf B. Irreversibility of Symptoms with Biotin Therapy in an Adult with Profound Biotinidase Deficiency. JIMD reports. 2017:36():117-120. doi: 10.1007/8904_2017_12. Epub 2017 Feb 21 [PubMed PMID: 28220409]
Porta F, Pagliardini V, Celestino I, Pavanello E, Pagliardini S, Guardamagna O, Ponzone A, Spada M. Neonatal screening for biotinidase deficiency: A 30-year single center experience. Molecular genetics and metabolism reports. 2017 Dec:13():80-82. doi: 10.1016/j.ymgmr.2017.08.005. Epub 2017 Sep 20 [PubMed PMID: 28971021]
Rajendiran A, Sampath S. Biotinidase deficiency--clinching the diagnosis rapidly can make all the difference! BMJ case reports. 2011 Sep 28:2011():. doi: 10.1136/bcr.07.2011.4494. Epub 2011 Sep 28 [PubMed PMID: 22679321]
Level 3 (low-level) evidenceWolf B. Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have". Genetics in medicine : official journal of the American College of Medical Genetics. 2012 Jun:14(6):565-75. doi: 10.1038/gim.2011.6. Epub 2012 Jan 5 [PubMed PMID: 22241090]
Szymańska E, Średzińska M, Ługowska A, Pajdowska M, Rokicki D, Tylki-Szymańska A. Outcomes of oral biotin treatment in patients with biotinidase deficiency - Twenty years follow-up. Molecular genetics and metabolism reports. 2015 Dec:5():33-35. doi: 10.1016/j.ymgmr.2015.09.004. Epub 2015 Oct 6 [PubMed PMID: 28649539]
Taitz LS, Leonard JV, Bartlett K. Long-term auditory and visual complications of biotinidase deficiency. Early human development. 1985 Sep:11(3-4):325-31 [PubMed PMID: 4054050]
Level 3 (low-level) evidenceProcter M, Wolf B, Crockett DK, Mao R. The Biotinidase Gene Variants Registry: A Paradigm Public Database. G3 (Bethesda, Md.). 2013 Apr 9:3(4):727-731. doi: 10.1534/g3.113.005835. Epub 2013 Apr 9 [PubMed PMID: 23550138]